Navigation Links
Abbott Begins Post-Approval Study of XIENCE V(TM) Drug Eluting Stent
Date:7/9/2008

XIENCE V USA Study to Evaluate Treatment of Coronary Artery Disease

Patients in Real-World Setting

ABBOTT PARK, Ill., July 9 /PRNewswire-FirstCall/ -- Abbott today announced the start of the XIENCE V(TM) USA post-approval study, with six hospital centers already recruiting and enrolling patients just one week after the U.S. Food and Drug Administration approved the XIENCE V(TM) Everolimus Eluting Coronary Stent System. The XIENCE V USA study will evaluate the safety and effectiveness of the XIENCE V drug eluting stent in a real-world clinical setting out to five years. Jack Jones, M.D., interventional cardiologist and medical director of the Stormont-Vail Catheterization Lab in Topeka, Kan., was one of the first physicians to enroll a patient into the study.

"XIENCE V is an important innovation that gives patients in the United States access to a next-generation drug eluting stent that has been shown in clinical trials to improve patient outcomes," said Dr. Jones. "During the stent procedure, we found it easy to deliver XIENCE V to the diseased portion of the vessel. With its combination of clinical efficacy and deliverability, I believe that XIENCE V will become a key advancement in the treatment of coronary artery disease."

The XIENCE V USA study is designed to evaluate at least 5,000 coronary artery disease patients treated with the XIENCE V drug eluting stent at approximately 250 centers across the United States. The primary endpoint of XIENCE V USA is a measure of stent thrombosis (formation of blood clots) every year out to five years, as defined by the Dublin/Academic Research Consortium (ARC). The ARC definition of late stent thrombosis was developed to eliminate variability in the definitions across various drug eluting stent trials.

The co-primary endpoint of the study is the composite rate of cardiac death and any heart attack (Q-wave or non-Q-wave myocardial infarction) in patients at one year.
'/>"/>

SOURCE Abbott
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Abbott Named One of the Best Places to Launch a Career by BusinessWeek
2. Martek Signs Multi-Year Worldwide Sole Source Supply Agreement with Abbott
3. Abbott Scientists Create One Molecule With Two Antibody Functions
4. Abbott Named to Science Magazines List of Top Employers in the Biotech and Pharmaceutical Industry
5. Abbotts HUMIRA(R) Receives Positive Opinion From EMEA for Treatment of Moderate to Severe Plaque Psoriasis
6. Abbott Declares 336th Consecutive Quarterly Dividend
7. Pfizer, Genentech, Amgen, Bayer, Wyeth, Abbott, Merck and Additional Leading Pharmaceutical Companies Participating During ExL Pharmas Fall Line Up!
8. Abbott to Present at JP Morgan Healthcare Conference
9. Abbott Announces Approval of First Fully Automated Blood Screening Test for HTLV-I/HTLV-II
10. Isis Announces Equity Investment in Ibis Biosciences Subsidiary by Abbott; Option Acquired to Purchase Remaining Ibis Equity
11. Abbott Receives FDA Approval for SIMCOR(R) (Niaspan(R) / simvastatin), a Novel Combination Medicine for Comprehensive Cholesterol Management
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... May 5, 2015 ImmunoCellular Therapeutics, Ltd. ... Gengos , President and Chief Executive Officer, will ... DATE:  Thursday, May 7, 2015     TIME:  11:30 ... > click the red "register/ watch presentations" ... interactive online event where investors are invited to ...
(Date:5/5/2015)... Oakland, CA (PRWEB) May 05, 2015 ... Database technology, today announced that its flagship product, AllegroGraph, ... recent Graph Database Market Update report. AllegroGraph ... by leveraging the W3C industry standards. Graph databases are skyrocketing ... two years, according to a recent DBMS ranking ...
(Date:5/5/2015)... , May 5, 2015 CytomX, a biotechnology ... today announced that Sean McCarthy , D. Phil., ... Antibody Day in New York ... McCarthy will present an overview of CytomX,s Probody pipeline, ... conjugate programs. About CytomX Therapeutics CytomX ...
(Date:5/5/2015)... (PRWEB) May 05, 2015 ... Hannifin distributor, announces the launch of http://www.cng.exoticautomation.com ... operators with a convenient way to purchase genuine ... products . , The new website provides ... vehicles with direct access to high performance products ...
Breaking Biology Technology:ImmunoCellular Therapeutics to Webcast Live at VirtualInvestorConferences.com on May 7 2Bloor Research Positions AllegroGraph as a ‘Champion’ in Burgeoning Graph Database Market 2Bloor Research Positions AllegroGraph as a ‘Champion’ in Burgeoning Graph Database Market 3Exotic Automation & Supply Launches Ecommerce Website 2
... Vermillion, Inc. (NASDAQ: VRML ), a molecular ... Trademark Office (USPTO) has issued a notice of allowance for ... claims cover the biomarker alpha1beta glycoprotein and biomarker combinations that ... "This will be our third patent for biomarkers that ...
... in hospitals is increasing. Bacteria acquire resistance to antibiotics ... genes, either from the surrounding environment or from other ... research (University of Lisbon) and the Instituto Gulbenkian de ... resistance are playing out in the bacterium Escherichia ...
... signals, for the first time, to assist in braking, ... to the thousands of car accidents that are caused ... technique that attaches electrodes to the scalp , the ... traffic sensors, could detect a driver,s intention to break ...
Cached Biology Technology:Vermillion Announces Notice of Allowance for Peripheral Artery Disease (PAD) Patent 2Vermillion Announces Notice of Allowance for Peripheral Artery Disease (PAD) Patent 3Bacterial resistance to antibiotics: The more they resist, the more they divide 2Put the brakes on using your brain power 2
(Date:4/9/2015)... JOSE, Calif. , April 9, 2015 ... human interface solutions, announced today that it will report ... on Thursday, April 23, 2015, after the close of ... for analysts and investors at 2:00 p.m. PT (5:00 ...   To participate on the live call, ...
(Date:4/2/2015)... In the current eight ... the strongest competitors, showing outstanding performance in recognition ... is capable of a throughput of 5.000.000 fingerprints ... be ten times faster than most competitors and ...      (Photo: http://photos.prnewswire.com/prnh/20150402/738673-a ) , ...
(Date:4/2/2015)... GOTHENBURG, Sweden , April 2, 2015 ... for its touch fingerprint sensor FPC1025 from the distributor ... Deliveries will commence during Q2 2015 although the major ... 2015. The sensors will be used by smartphone manufacturers ... of 110 MSEK is included in the communicated revenue ...
Breaking Biology News(10 mins):Synaptics to Report Third Quarter Results on April 23 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 110 Million 2
... German . , Berlin, 2 September 2009 - ... ecosystems - from forests and mangroves to wetlands and river ... change and climate-proofing vulnerable economies. This is among the ... Economics of Ecosystems and Biodiversity (TEEB), a project launched by ...
... JACKSONVILLE, Fla. In a biological rendition of fiction,s ... the Mayo Clinic campus in Florida and Harvard Medical School ... development can actually spur the spread of tumors. ... Molecular and Cellular Biology , found that FOXO3a, a transcription ...
... that comes to mind when people think of Alzheimer,s disease, ... and France, this might change. That,s because these researchers have ... might be the key that unlocks an entirely new class ... report published online in The FASEB Journal ( ...
Cached Biology News:Time to tap climate change-combating potential of the world's ecosystems 2Time to tap climate change-combating potential of the world's ecosystems 3Time to tap climate change-combating potential of the world's ecosystems 4Time to tap climate change-combating potential of the world's ecosystems 5Mayo Clinic researchers find that protein believed to protect against cancer has a Mr. Hyde side 2Scientists begin to untangle root cause of Alzheimer's disease 2
Rabbit polyclonal to Tryptophanyl tRNA synthetase ( Abpromise for all tested applications). Antigen: Recombinant full length protein (Human): Tryptophanyl tRNA synthetase Entrez Gene ID: 745...
Goat polyclonal to FBXO2 ( Abpromise for all tested applications). entrezGeneID: 26232 SwissProtID: Q9UK22...
Rat monoclonal to UGGT ( Abpromise for all tested applications)....
... anti-phospho-FAK (Ser843) Immunogen: ... region encompassing the human, mouse, and ... Accession Number: NM_153831 ... evaluated by immunoblot. ...
Biology Products: